O
OXGENE
Combination of precision engineering and breakthrough science, together with advanced robotics and bioinformatics, accelerates the rational design, discovery and manufacture of cell and gene therapies
About OXGENE
OXGENE, a leader in mammalian cell engineering, operates at the forefront of cell and gene therapy innovation. The company provides advanced technology platforms and expert solutions that accelerate the discovery, development, and manufacture of these therapies. OXGENE serves biotech and pharmaceutical companies, offering services that range from high-titre viral vector production to CRISPR-based gene editing and antibody manufacturing. The company operates in the biotech and pharmaceutical markets, leveraging its integrated smart labs and robotic production processes to deliver high-quality, scalable solutions. OXGENE's business model is service-based, generating revenue through project-based contracts and long-term partnerships with its clients. The Connex platform, a CFR-compliant system, is central to OXGENE's operations, providing real-time project updates and powerful AI-driven insights by connecting all scientific data storage and management aspects. This integrated approach ensures efficiency, quality control, and excellent customer service, making OXGENE a key player in the cell and gene therapy space.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2011
- Headquarters
- Oxford, United Kingdom
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 30.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Medical Robots, Tech for Biotech and Pharma, Collaborative Robots, BIA Techbio UK, Techbio, Hard Tech
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning OXGENE.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VC✓Equity / VC | Jul 2025 | $990K | — | Midlands Engine Investment Fund | ↗ |
| ACQUISITION✓Exit | Mar 2021 | $135M | $135M | WuXi AppTec | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for OXGENE is 170 monthly website visits, down 83% over the last three months. OXGENE's team declined 81.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Mercia Asset Management
Series A1 investor entered at this stage
Invesco Perpetual
Series B and later1 investor entered at this stage
Midlands Engine Investment Fund
Other known investors3 additional known investors
University of Oxford
WuXi AppTec
Mercia Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OXGENE on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OXGENE’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.